Tango Therapeutics Stock Performance
| TNGX Stock | USD 3.10 0.16 5.44% |
The entity has a beta of -2.09, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Tango Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Tango Therapeutics is expected to outperform it. At this point, Tango Therapeutics has a negative expected return of -1.1%. Please make sure to validate Tango Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Tango Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Tango Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 5.44 | Five Day Return 5.8 | Year To Date Return (68.94) | Ten Year Return (69.70) | All Time Return (69.70) |
1 | Insider Trading | 10/10/2024 |
2 | Disposition of 625000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 7.05 subject to Rule 16b-3 | 10/21/2024 |
3 | Disposition of 250000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.78 subject to Rule 16b-3 | 10/22/2024 |
4 | Disposition of 633000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.87 subject to Rule 16b-3 | 10/25/2024 |
5 | Acquisition by Davis Aaron I. of 65000 shares of Tango Therapeutics at 10.93 subject to Rule 16b-3 | 11/01/2024 |
6 | Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program | 11/06/2024 |
7 | Disposition of 1143124 shares by Ecor1 Capital, Llc of Tango Therapeutics at 2.9171 subject to Rule 16b-3 | 11/07/2024 |
8 | Tango Therapeutics, Inc. Insider Boxer Capital Management, Llc Sells 3,080,000 Shares of Stock | 11/08/2024 |
9 | Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.62 subject to Rule 16b-3 | 11/14/2024 |
10 | Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.78 subject to Rule 16b-3 | 11/18/2024 |
11 | Tango Therapeutics, Inc. Director Purchases 37,800.00 in Stock | 11/19/2024 |
12 | Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference | 11/27/2024 |
13 | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/03/2024 |
14 | Tango Therapeutics, Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBeat | 12/09/2024 |
| Begin Period Cash Flow | 64 M |
Tango |
Tango Therapeutics Relative Risk vs. Return Landscape
If you would invest 745.00 in Tango Therapeutics on September 24, 2024 and sell it today you would lose (435.00) from holding Tango Therapeutics or give up 58.39% of portfolio value over 90 days. Tango Therapeutics is currently does not generate positive expected returns and assumes 6.8357% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Tango, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tango Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tango Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tango Therapeutics, and traders can use it to determine the average amount a Tango Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1602
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TNGX |
Estimated Market Risk
| 6.84 actual daily | 60 60% of assets are less volatile |
Expected Return
| -1.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tango Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tango Therapeutics by adding Tango Therapeutics to a well-diversified portfolio.
Tango Therapeutics Fundamentals Growth
Tango Stock prices reflect investors' perceptions of the future prospects and financial health of Tango Therapeutics, and Tango Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tango Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.84) % | ||||
| Operating Margin | (2.83) % | ||||
| Current Valuation | 77.34 M | ||||
| Shares Outstanding | 107.42 M | ||||
| Price To Book | 1.45 X | ||||
| Price To Sales | 7.68 X | ||||
| Revenue | 36.53 M | ||||
| Gross Profit | (81.05 M) | ||||
| EBITDA | (111.76 M) | ||||
| Net Income | (101.74 M) | ||||
| Cash And Equivalents | 416.36 M | ||||
| Cash Per Share | 4.73 X | ||||
| Total Debt | 38.92 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.76 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (117.98 M) | ||||
| Earnings Per Share | (1.15) X | ||||
| Market Capitalization | 333 M | ||||
| Total Asset | 402.57 M | ||||
| Retained Earnings | (371.26 M) | ||||
| Working Capital | 300.6 M | ||||
About Tango Therapeutics Performance
Evaluating Tango Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tango Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tango Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 59.09 | 86.15 | |
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.40) | (0.42) |
Things to note about Tango Therapeutics performance evaluation
Checking the ongoing alerts about Tango Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tango Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tango Therapeutics generated a negative expected return over the last 90 days | |
| Tango Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 36.53 M. Net Loss for the year was (101.74 M) with loss before overhead, payroll, taxes, and interest of (81.05 M). | |
| Tango Therapeutics currently holds about 416.36 M in cash with (117.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tango Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Tango Therapeutics, Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBeat |
- Analyzing Tango Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tango Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tango Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tango Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tango Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tango Therapeutics' stock. These opinions can provide insight into Tango Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.